Saturday 17 October 2026
Export ANVS’s income statement to Excel — free account
Annovis Bio, Inc.
ANVS Healthcare Biotechnology
In the quarter to June 2026, EPS fell 25.0% and free cash flow fell 329.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.99
0.06
−5.71%
Follow ANVS
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | 2.42 | 7.42 | 8.39 | 5.42 | 4.21 | 1.11 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | 10.61 | 132.00 | 23.91 | 23.89 | 20.00 | 5.60 | |||||
| People | |||||||||||||||
| People | Employees | — | — | 2 | 2 | 2 | 3 | 5 | 6 | 8 | 8 | ||||
| Revenue/emp, $m | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | |||||
| EBT | — | (1) | (1) | (1) | (5) | (14) | (25) | (56) | (25) | (29) | |||||
| EBT margin, % | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | 0 | (1) | (1) | (5) | (14) | (25) | (56) | (25) | (29) | |||||
| Depreciation | — | — | — | 0 | 0 | — | — | — | — | — | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | (0.10) | (2.57) | (3.50) | (0.87) | (1.90) | (3.10) | (6.23) | (2.02) | (1.40) | |||||
| Cash flow | — | (0.08) | (2.01) | (1.68) | (0.63) | (1.20) | (2.12) | (4.43) | (1.80) | (1.25) | |||||
| Capex | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | — | (0.08) | (2.01) | (1.68) | (0.63) | (1.20) | (2.12) | (4.43) | (1.80) | (1.25) | |||||
| Book value | — | (0.02) | (27.32) | (30.31) | 1.20 | 5.83 | 3.47 | (0.86) | 0.76 | 0.82 | |||||
| Shares, m | — | 7 | 0 | 0 | 6 | 8 | 8 | 9 | 12 | 21 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | (1) | (1) | 0 | (4) | (9) | (17) | (40) | (22) | (26) | ||||
| Capex | — | — | — | — | — | — | — | — | — | — | |||||
| Free cash flow | — | (1) | (1) | 0 | (4) | (9) | (17) | (40) | (22) | (26) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | 0 | (1) | (1) | 8 | 44 | 28 | 6 | 10 | 17 | ||||
| Total debt | — | — | — | 0 | — | — | — | — | — | — | |||||
| Net debt | — | 0 | 0 | 0 | (8) | (46) | (28) | (6) | (11) | (20) | |||||
| Shareholders’ equity | — | 0 | (8) | (9) | 8 | 44 | 28 | (8) | 9 | 17 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | (333.64) | (2,799.61) | (169.68) | (118.27) | (53.54) | (61.76) | (243.15) | (203.78) | (164.85) | ||||
| ROIC | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | 9.37 | 9.81 | 12.26 | 1,055.05 | (55.68) | (69.57) | (546.40) | (3,158.89) | (220.61) | |||||
Negative figures in brackets.
Charts ten years each
Annovis Bio, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| CLNN Clene Inc. | $47.0M | — (loss-making) | — (loss-making) | +233.33% (above 0%: growing) | n/m | +45.43% (above 0%: growing) | 60.00% | (5,941.11%) | Compare |
| TVGN Tevogen Inc. | $46.1M | — (loss-making) | — | — | n/m | +5.78% (above 0%: growing) | — | 0.00% | Compare |
| INMB INmune Bio, Inc. | $45.8M | — (loss-making) | — (loss-making) | +8.70% (above 0%: growing) | n/m | +55.39% (above 0%: growing) | 100.00% | 0.00% | Compare |
| IMA ImageneBio, Inc. | $45.7M | — (loss-making) | — (loss-making) | −60.08% (below 0%: shrinking) | n/m | +23.76% (above 0%: growing) | 100.00% | 0.00% | Compare |
| SER Serina Therapeutics, Inc. | $45.5M | — (loss-making) | — (loss-making) | +2,500.00% (above 0%: growing) | n/m | −76.82% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| ANVS Annovis Bio, Inc. | $44.8M | — (loss-making) | — | — | n/m | −329.18% (below 0%: shrinking) | — | 0.00% | |
| ALDX Aldeyra Therapeutics, Inc. | $44.5M | — (loss-making) | — | — | n/m | +46.09% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CELU Celularity, Inc. | $43.2M | — (loss-making) | — (loss-making) | −66.34% (below 0%: shrinking) | n/m | +148.35% (above 0%: growing) | 62.25% | (263.47%) | Compare |
| DWTX Dogwood Therapeutics, Inc | $42.5M | — (loss-making) | — | — | n/m | +10.31% (above 0%: growing) | — | 0.00% | Compare |
| Median of peers | $45.6M | — | — | +8.70% | — | +34.60% | 81.13% | 0.00% |
Annovis Bio, Inc. (ANVS) key facts
- Annovis Bio, Inc. (ANVS) is a Biotechnology company in the Healthcare sector, listed on the New York Stock Exchange.
- As of October 16, 2026, ANVS traded at $0.99, a market capitalization of $44.8 million.
- Return on equity was −220.6% and debt-to-equity 0.00.